BeStock  
Stocks › Biotechnology › CRSP

CRISPR Therapeutics CRSP

$39.10 +$0.17 (+0.44%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $39.50 +1.02%
Open$38.18
Prev close$38.93
Day range$38.15 – $40.17
Volume3.32M
Market cap$3.79B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$12.32M+1,325.1% YoY
Operating profit-$118.37M+10.4% YoY
Net profit-$111.44M-4.7% YoY
Diluted EPS-$1.15+1.7% YoY
Free cash flow-$89.27M-5.4% YoY
Operating cash flow-$89.68M

Revenue, last 8 quarters

$35.0MDec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$1.0MMar '26$10.0MJun '26$12.3MSep '26

Net profit, last 8 quarters

$-37.3MDec '24$-136.0MMar '25$-208.5MJun '25$-106.4MSep '25$-130.6MDec '25$-122.9MMar '26$-91.2MJun '26$-111.4MSep '26

Diluted EPS by quarter

-0.44Dec '24-1.58Mar '25-2.40Jun '25-1.17Sep '25-1.37Dec '25-1.28Mar '26-0.94Jun '26-1.15Sep '26

Free cash flow by quarter

$-50.3MDec '24$-54.2MMar '25$-139.0MJun '25$-84.7MSep '25$-93.1MDec '25$-109.4MMar '26$-86.6MJun '26$-89.3MSep '26

Annual revenue

$543.0KFY20$913.1MFY21$436.0KFY22$370.0MFY23$35.0MFY24$0.0FY25

Profitability & balance sheet

Gross margin-676.9%
Operating margin-2,221.7%
Net margin-1,955.7%
Return on equity-25.6%
Return on assets-19.0%
Return on invested capital-20.0%
Current ratio16.21
Liabilities / assets35.5%
Cash & investments$2.27B
Total debt$761.15M
Net cash (debt)$1.51B

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $12.67M $10.18M $1.46M $3.51M $864,000.00
Total Operating Revenue $12.32M $10.00M $1.00M $0.00 $0.00
Cost of Revenue $41.28M $40.27M $45.95M $213.48M $53.70M
Gross Profit -$28.96M -$30.27M -$44.95M -$213.48M -$53.70M
Operating Expense $89.41M $84.52M $85.30M $354.84M $101.06M
Selling and Admin Expenses $17.87M $17.55M $17.18M $73.54M $18.40M
-General & Admin Expense $17.87M $17.55M $17.18M $73.54M $18.40M
Research & Development $71.89M $67.15M $68.57M $284.81M $83.53M
Other Operating Expenses -$346,000.00 -$181,000.00 -$458,000.00 -$3.51M -$864,000.00
Operating Profit -$118.37M -$114.80M -$130.25M -$568.32M -$154.76M
Other Income (Expense) $7.01M $24.60M $8.16M -$9.65M $24.77M
Special Income (Charges) -$11.68M -$2.47M – -$96.25M $0.00
-Less:Other Special Charges $11.68M $2.47M – $96.25M $0.00
Other Non-Operating Income (Expenses) $18.68M $27.08M $8.16M $86.61M $24.77M
Pretax Profit -$111.36M -$90.19M -$122.09M -$577.97M -$130.00M
Tax $74,000.00 $960,000.00 $839,000.00 $3.63M $614,000.00
Net Profit -$111.44M -$91.15M -$122.93M -$581.60M -$130.61M
Profit from Continuing Operations -$111.44M -$91.15M -$122.93M -$581.60M -$130.61M
Net Income to Parent Company -$111.44M -$91.15M -$122.93M -$581.60M -$130.61M
Net Income to Common Stockholders -$111.44M -$91.15M -$122.93M -$581.60M -$130.61M
Basic EPS -$1.15 -$0.94 -$1.28 -$6.47 -$1.37
Diluted EPS -$1.15 -$0.94 -$1.28 -$6.47 -$1.37

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $2.56B $2.65B $2.73B $2.27B $2.27B
Total Current Assets $2.29B $2.37B $2.45B $1.99B $1.99B
Cash and Cash Equivalents & Short-Term Investments $2.27B $2.36B $2.44B $1.98B $1.98B
-Cash and Cash Equivalents $192.03M $291.34M $423.31M $347.56M $347.56M
-Short Term Investments $2.08B $2.07B $2.02B $1.63B $1.63B
Other Current Assets $12.53M $7.42M $6.58M $9.84M $9.84M
Total Non-Current Assets $271.33M $279.00M $277.46M $279.57M $279.57M
Net PPE $226.91M $233.66M $240.85M $247.58M $247.58M
-Gross PPE $330.71M $333.25M $336.19M $338.63M $338.63M
-Accumulated Depreciation -$103.80M -$99.59M -$95.34M -$91.05M -$91.05M
Investments and Advances $4.02M – – – –
-Available for Sale Securities $4.02M – – – –
Other Non-Current Assets $40.41M $45.34M $36.61M $32.00M $32.00M
Total Liabilities $908.34M $904.22M $911.26M $343.43M $343.43M
Total Current Liabilities $140.96M $132.90M $136.29M $149.12M $149.12M
Payables $20.72M $11.80M $14.29M $12.25M $12.25M
-Accounts Payable $20.59M $11.31M $13.65M $11.14M $11.14M
-Total Tax Payable $132,000.00 $494,000.00 $638,000.00 $1.11M $1.11M
Current Accrued Expenses $82.02M $70.28M $74.93M $89.41M $89.41M
Short-Term Debt and Capital Lease Obligation $18.68M $18.65M $18.61M $18.58M $18.58M
-Current Capital Lease Obligation $18.68M $18.65M $18.61M $18.58M $18.58M
Current Deferred Liabilities $2.55M $15.19M $15.34M $15.77M $15.77M
Other Current Liabilities $17.00M $16.98M $13.11M $13.11M $13.11M
Total Non-Current Liabilities $767.38M $771.32M $774.98M $194.31M $194.31M
Long Term Debt and Capital Lease Obligation $761.15M $765.10M $769.03M $188.17M $188.17M
-Long Term Debt $586.93M $586.20M $585.47M – –
-Long Term Capital Lease Obligation $174.21M $178.90M $183.56M $188.17M $188.17M
Other Non-Current Liabilities $6.24M $6.22M $5.95M $6.14M $6.14M
Total Equity $1.65B $1.75B $1.81B $1.92B $1.92B
Stockholders' Equity $1.65B $1.75B $1.81B $1.92B $1.92B
Capital Stock $3.15M $3.13M $3.12M $3.09M $3.09M
-Common Stock $3.15M $3.13M $3.12M $3.09M $3.09M
Additional Paid-In Capital $3.93B $3.91B $3.88B $3.86B $3.86B
Retained Earnings -$2.27B -$2.16B -$2.07B -$1.95B -$1.95B
Less: Treasury Stock -$60,000.00 -$60,000.00 -$60,000.00 -$60,000.00 -$60,000.00
Gains/Losses Not Affecting Retained Earnings -$14.08M -$4.63M -$1.94M $4.82M $4.82M
Receivables – – – $0.00 $0.00
-Accounts Receivable – – – $0.00 $0.00
Non-Current Deferred Liabilities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$89.68M -$83.50M -$108.90M -$345.01M -$92.55M
Net cash flow from continuing operations -$89.68M -$83.50M -$108.90M -$345.01M -$92.55M
Net Income from Continuing Operations -$111.44M -$91.15M -$122.93M -$581.60M -$130.61M
Depreciation & Depletion & Amortization $4.24M $4.28M $4.32M $19.48M $5.66M
Other Non-Cash Items -$2.60M -$10.24M $8.80M $72.73M -$8.31M
Change in Working Capital $2.15M -$3.70M -$15.41M $71.88M $22.64M
-Change in Receivables $0.00 $0.00 $0.00 $25.00M $0.00
-Change in Prepaid Assets -$4.18M -$841,000.00 -$247,000.00 $3.34M $3.85M
-Change in Payables and Accrued Expense $20.62M -$5.31M -$13.02M $44.89M $4.42M
-Change in Other Current Liabilities $32,000.00 $4.15M -$199,000.00 $4.26M $13.55M
-Change In Other Working Capital -$14.32M -$1.70M -$1.95M -$5.61M $810,000.00
Net cash flow from investing -$14.09M -$55.66M -$410.74M -$31.81M $37.20M
Net Cash Flow from Continuing Investing Activities -$14.09M -$55.66M -$410.74M -$31.81M $37.20M
Net PPE Purchase and Sale -$414,000.00 -$648,000.00 -$504,000.00 -$914,000.00 -$517,000.00
Net Intangibles Purchase and Sale $825,000.00 – – -$25.00M $0.00
Net Investment Purchase and Sale -$14.50M -$52.54M -$410.24M -$5.89M $37.72M
Financing Cash Flow $4.45M $7.18M $591.91M $426.03M $116.41M
Net Cash Flow from Continuing Financing Activities $4.45M $7.18M $591.91M $426.03M $116.41M
Net Common Stock Issuance $0.00 – – $398.09M $111.49M
Net Preferred Stock Issuance $0.00 $0.00 $600.00M – –
Proceeds from Stock Option Exercised $4.45M $8.30M $6.16M $27.94M $4.92M
Net Other Financing Charges $0.00 -$400,000.00 -$14.25M – –
Ending Cash Balance $200.03M $299.34M $431.31M $359.08M $359.08M
Net Change in Cash -$99.32M -$131.98M $72.27M $49.21M $61.06M
Beginning Cash Balance $299.34M $431.31M $359.08M $309.78M $298.02M
Effect of Exchange Rate Changes $6,000.00 $6,000.00 -$32,000.00 $95,000.00 $1,000.00
Free Cash Flow -$89.27M -$86.62M -$109.40M -$370.93M -$93.07M

Discussion

No comments yet — be the first to weigh in on CRSP.

Sign in to join the discussion.

Scroll to Top